Who are Influenza vaccine GSK2340272A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quadrivalent Influenza Virus Split Vaccine, SD Fluzone Vaccine, Vaxigrip Tetra Sanofi Pasteur Europe, ccIIV4, Seasonal trivalent influenza vaccine, Anflu®, SD-QIV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/influenza-vaccine-gsk2340272a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Influenza vaccine GSK2340272A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influenza vaccine GSK2340272A (Influenza vaccine GSK2340272A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology.

phase 3 Influenza vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Influenza vaccine GSK2340272A (Influenza vaccine GSK2340272A) — GlaxoSmithKline. GSK2340272A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Influenza vaccine GSK2340272A TARGET	Influenza vaccine GSK2340272A	GlaxoSmithKline	phase 3	Influenza vaccine
Quadrivalent Influenza Virus Split Vaccine	Quadrivalent Influenza Virus Split Vaccine	Shanghai Institute Of Biological Products	marketed	Inactivated split influenza vaccine
SD Fluzone Vaccine	SD Fluzone Vaccine	Insight Therapeutics, LLC	marketed	inactivated influenza vaccine
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)
ccIIV4	ccIIV4	Vanderbilt University Medical Center	marketed	Inactivated influenza vaccine
Seasonal trivalent influenza vaccine, Anflu®	Seasonal trivalent influenza vaccine, Anflu®	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
SD-QIV	SD-QIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

GlaxoSmithKline · 8 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Seqirus · 2 drugs in this class
MedImmune LLC · 1 drug in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Protein Sciences Corporation · 1 drug in this class
ModernaTX, Inc. · 1 drug in this class
Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Influenza vaccine GSK2340272A — Competitive Intelligence Brief. https://druglandscape.com/ci/influenza-vaccine-gsk2340272a. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab